Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation

Set Alert for Legislation

Latest From Legislation

DTC Ad Price Disclosure Provision Stripped From US Funding Bill

Even though measure was blocked in Congress, it may still advance through regulation.

Pricing Debate Advertising, Marketing & Sales

Will CBO Score CREATE Momentum For Generic Bill's Passage?

Strong savings estimate – and brand pharma's need to have pay-fors for its own legislative priorities – could finally get bill allowing generic companies to sue brand sponsors for access to samples.
Generic Drugs Legislation

Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple

US Congress wants to prohibit contracts that prevent pharmacists from alerting customers to opportunities to save money by paying out of pocket. Legislation is moving rapidly, but once again, a simple fix to a drug pricing issue may have unintended consequences.
Pharmacy Benefit Management Pricing Debate

REMS Abuse Website: All Sizzle, No Steak?

AAM President Davis contends he hasn't seen any evidence showing that reference listed drug access inquiries webpage has changed innovator behavior.
Pricing Debate Regulation

India Builds In Transaction Audits For Monitoring E-Pharmacies

Transaction audits are proposed as part of checks to monitor e-pharmacies in India, though there are some concerns on whether the well-meaning measure can become a source of “inspector raj” and stifle the fledgling industry.
India Regulation

PBMs’ Impact On Drug Prices Probed By House Committee Leaders

Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.

Pharmacy Benefit Management Legislation
See All
UsernamePublicRestriction

Register